beta-1,3-glucan

also known as NDG · SDG

Developed for: conjunctivitis
Investigated by: Kyoto Prefectural University of Medicine · Meiji University of Oriental Medicine

today NCT00276445 · Ph 4

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT00276445	Jan → Jun 2004	conjunctivitis	Meiji University of Oriental Medicine	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	beta-1,3-glucan	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00276445 ↗
Known as	NDG	“non-dispersed beta-1,3-glucan (NDG)” NCT00276445 ↗
Known as	SDG	“superfine dispersed beta-1,3-glucan (SDG)” NCT00276445 ↗